Compare DexCom, Inc. (DXCM) vs Lithium Americas Corp (LAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Lithium Americas Corp — how do they compare? DexCom, Inc. trades at $83.9 (market cap $31.86B), while Lithium Americas Corp trades at $2.34 (market cap $850.38M). The key difference: DexCom, Inc. is far larger — about 37.5× Lithium Americas Corp's market cap, and DexCom, Inc. is trading nearer its 52-week high, Lithium Americas Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Lithium Americas Corp for 27 Days on average.
| DXCM | LAC | |
|---|---|---|
Market Cap | $31.86B | $850.38M |
Volume | 3,607,070 | 8,804,637 |
Sector | Health | Basic Materials |
52-Week High | $92.34 | $10.05 |
52-Week Low | $54.84 | $2.36 |
Typical Hold Time | 62 Days | 27 Days |
Enterprise Value | $31.32B | $1.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
Lithium Americas (LAC) trades at $2.34, down 2.9% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company shows negative profitability metrics with ROE at -9.56% and ROA at -3.99%, though it has beaten earnings expectations in recent quarters. Cash flow remains supported by financing activities as the company invests heavily in Thacker Pass development. Analyst consensus is mixed with 7 buy ratings and 8 hold ratings, with a $4.00 price target representing 71% upside potential.
LAC presents a high-risk, high-reward opportunity as it transitions from development to execution phase. The primary catalyst is successful construction and operation of Thacker Pass, but investors face significant execution risk, negative cash flow from operations, and lithium price volatility. The stock trades at a discount to book value (P/B 0.6), offering potential upside if operational milestones are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Lithium Americas Corp
Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.
Read more on LAC →
